XNK Therapeutics granted SEK1m by Sweden’s Vinnova to partner in AdBIOPRO

January 29, 2018

XNK Therapeutics AB (“XNK”) today announced that the Swedish government-sponsored innovation agency Vinnova has granted XNK SEK1 million to partner in The Competence Centre for Advanced BioProduction by Continuous Processing, AdBIOPRO.

“We are excited to receive this funding to join AdBIOPRO,” said Karin Mellström, CEO of XNK Therapeutics. “Joining AdBIOPRO will help us advance our proprietary platform technology and bring us in contact with some of the top talent in bioproduction.”

For more information, please contact:
Karin Mellström, CEO, XNK Therapeutics
E-mail: info@xnktherapeutics.com

About XNK Therapeutics AB
XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. The company’s platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow’s cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

About XNK Therapeutics’ technology platform
The platform has ideal properties to produce autologous NK cell-based drug candidates for targeting malignant diseases across a wide range of indications in mono- and combination therapy. It encompasses a unique closed manufacturing system for development of the NK cell-based products. The process includes a selective expansion and activation of NK cells from peripheral blood of patients with cancer. The product is produced in less than three weeks. It is delivered to the clinic upon need, where the product is thawed and infused into the patient without any further processing. The product has demonstrated an up to 10-year stability in liquid nitrogen.